Repligen Corporation announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax. This appointment expands the size of Repligen?s board from eight to nine members. Ms. Pax brings to Repligen over 25 years of experience leading the development and execution of growth strategies for global companies.

This includes eight years with Thermo Fisher Scientific, where, from 2016?2020, she served as Vice President, Strategy and Innovation for the clinical supply chain business. In this role, she led strategic planning, developed customer-facing innovation programs, and drove the business case for the company?s multi-billion acquisition of Patheon, a leading biopharmaceutical contract manufacturer. In addition to her role as Vice President Strategy and Innovation at Thermo Fisher, Ms. Pax?s background includes her position as Senior Director, Corporate Development & Strategy at Thermo Fisher from 2013?2016, where she led post-merger commercial integration for the company?s acquisition of Life Technologies.

Earlier in her career with Thermo Fisher, Maggie was the Senior Director, Portable Analytical Instrumentation from 2012-2013. From 1989-2000 Maggie was with Phillips Healthcare, a leading medical device company, where she held senior leadership roles in Business Development, Marketing and Product Management. Between her Phillips and Thermo Fisher roles, Maggie held a number of entrepreneurial leadership positions, including as Vice President, Business and Clinical Development for five years (2006-2011) at Microchips Biomedical, an MIT startup company that was acquired by Daré Bioscience.

Ms. Pax is currently an independent board director for Alimera Sciences, a Nasdaq-listed pharmaceutical company with retinal treatments, and Jellagen, a privately-held UK company developing novel wound care products. She also sits on the board of the U.S. subsidiary of BioPorto A/S, a Danish-based kidney biomarker company. Ms. Pax advises a range of healthcare and life sciences companies on business strategy, commercial growth and partnerships.

Maggie received her BA from the College of Holy Cross, and has an MBA from Harvard Business School, where she serves as a board member of the Harvard Business School Healthcare Alumni Association.